Diligence memo · auto-generated · as of July 2, 2026

Opko Health, Inc.

Opko Health, Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Opko Health, Inc. operates in Pharmaceuticals, based in Miami.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Opko Health, Inc. has raised $206M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).

Largest single filing: $175M on 2013-01-30.

Most recent recorded round closed around 2013-01-30.

Valuation (modeled)modeled

Provath models Opko Health, Inc. at approximately $6.2B (range $833M–$13.5B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.08× the median modeled value of Series D+ Pharmaceuticals companies in 2013–2015 (6 peers) — value vs value, same stage and era. Within the normal band (108% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 44 months.

Last raise 13.4 yr ago; this sector typically re-raises about every 13 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 5.6× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 97% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 99% of those peers.

Closest niche peers: Kv Pharmaceutical Co /De/, Clovis Oncology, Inc., Horizon Pharma, Inc., HLS Therapeutics Inc., Biotie Therapies Corp..

Peoplefiled

15 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.